Abstract: A server in a subscriber television network receives service instances from a headend of the subscriber television network. The server is adapted to encrypt according to an encryption scheme and re-transmit service instances to a client-receiver. The server reformats the service instance from a first format into a second format the client-receiver can access the service instance.

Abstract: A master device interactively distributes a television signal to a remote device for remote display with low latency between a user input and a television signal change.

Abstract: A master device interactively distributes a television signal to a remote device for remote display with low latency between a user input and a television signal change.

Abstract: The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalac

Abstract: A master device interactively distributes a television signal to a remote device for remote display with low latency between a user input and a television signal change.

Abstract: A method for providing an interactive program guide (IPG) includes receiving from a user a request for an IPG, and providing the user with an IPG that includes listings that were received by a digital home communication terminal (DHCT) via a subscriber television network, as well as other listings that were not received by the DHCT via the subscriber television network.

Abstract: The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalac

Abstract: A method for providing an interactive program guide (IPG) includes receiving from a user a request for an IPG, and providing the user with an IPG that includes listings that were received by a digital home communication terminal (DHCT) via a subscriber television network, as well as other listings that were not received by the DHCT via the subscriber television network.

Abstract: A server in a subscriber television network receives service instances from a headend of the subscriber television network. The server is adapted to encrypt according to an encryption scheme and re-transmit service instances to a client-receiver. The server reformats the service instance from a first format into a second format the client-receiver can access the service instance.

Abstract: A server in a subscriber television network receives service instances from a headend of the subscriber television network. The server is adapted to encrypt according to an encryption scheme and re-transmit service instances to a client-receiver. The server reformats the service instance from a first format into a second format the client-receiver can access the service instance.

Abstract: The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalac

Abstract: The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalac

Abstract: Systems and methods are disclosed for providing objects to a remote digital home communication terminal (remote DHCT) via a gateway device located at a customer premises. One such method, among others, includes receiving a message from a remote DHCT requesting a carousel object, receiving the carousel object from a server device, and transmitting the carousel object to the remote DHCT.

Abstract: Included are systems and methods for providing access. At least one embodiment of a system includes a host configured to receive at least one tool for providing conditional access and a secure processor configured to receive conditional access logic. Some embodiments of the conditional access logic are configured to send at least one configuration message for configuring the at least one tool at the host component for operation with the received access logic.

Abstract: A server in a subscriber television network receives service instances from a headend of the subscriber television network. The server is adapted to encrypt according to an encryption scheme and re-transmit service instances to a client-receiver. The server reformats the service instance from a first format into a second format the client-receiver can access the service instance.

Abstract: A server in a subscriber television network receives service instances from a headend of the subscriber television network. The server is adapted to encrypt according to an encryption scheme and re-transmit service instances to a client-receiver. The server reformats the service instance from a first format into a second format the client-receiver can access the service instance.

Abstract: The invention is directed to alkylquinoline and alkylquinazoline compounds of Formula C: wherein R1, R2, R99, and X are as defined herein, the use of such compounds in the sysnthesis of protein tyrosine kinase inhibitors, particularly inhibitors of FLT3 and/or c-kit and/or TrkB.

Abstract: The invention is directed to aminopyrimidine compounds of Formula I: where R3, B, Z, r and R1 are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

Abstract: The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from alkylquinoline and alkylquinazoline compounds of Formula I?: where R1, R2, R3, Z, G, Q and X are as defined herein. Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.

Abstract: The invention is directed to aminoquinoline and aminoquinazoline compounds of Formula I: where R1, R2, R3, B, Z, Q, p, q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.